Proteins in AFs were robotically excised and processed to generate tryptic digest Tryptic peptides were analyzed by mass spectrometry using a PerSeptive Biosystems Voyager- DE<sup>TM</sup> STR Matrix-Assisted Laser Desorption Ionization Time-of-Flight (MALDI-TOF) mass spectrometer, and selected tryptic peptides were analyzed by tandem mass spectrometry (MS/MS) using a Micromass Quadrupol Time-of-Flight (Q-TOF) mass spectrometer (Micromass, Altrincham, U.K.) equipped with a Nanoflow<sup>TM</sup> electrospray Z-spray source. For partial amino acid sequencing and identification of APIs uninterpreted tandem mass spectra of tryptic peptides were searched using the SEQUEST search program (Eng et al., 1994, J. Am. Soc. Mass Spectrom. 5:976-989), version v.C.1. Criteria for database identification included: the cleavage specificity of trypsin; the detection of a suite of a, b and y ions in peptides returned from the database, and a mass increment for all Cys residues to account for carbamidomethylation. The database searched was database constructed of protein entries in the non-redundant database held by the National Centre for Biotechnology Information (NCBI) which is accessible at http://www.ncbi.nlm.nih.gov/. Following identification of proteins through spectral-spectral correlation using the SEQUEST program, masses detected in MALDI-TOF mass spectra were assigned to tryptic digest peptides within the proteins identified. In cases where no proteins could be identified through searching with uninterpreted MS/MS spectra of tryptic digest peptides using the SEQUEST program, tandem mass spectra of the peptides were interpreted manually, using methods known in the art. (In the case of interpretation of low-energy fragmentation mass spectra of peptide ions see Gaskell et al., 1992, Rapid Commun. Mass Spectrom. 6:658-662).

## In the claims:

Please cancel claims 51-55. Additionally, please amend claims 59-67 as follows:



- 59. (Twice Amended) A method for screening, diagnosis, or prognosis of Alzheimer's disease in a subject, the method comprising detecting, in a biological sample, API-6, wherein a decreased level of said API-6, relative to a control sample or a reference range, indicates the presence or degree of Alzheimer's disease or a subject at risk of developing Alzheimer's disease.
- 60. (Twice Amended) The method of claim 59 wherein the step of detecting comprises:

17/485565.3 - 2 -